Sensitization of tumor cells by targeting histone deacetylases

Biochemical Pharmacology

Volumn 83, Issue 8, 2012, Pages 987-994

  Perego, Paola ^a   Zuco, Valentina ^a   Gatti, Laura ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Drug resistance; Histone deacetylases

Indexed keywords

ADAROTENE; BORTEZOMIB; CURCUMIN; DACINOSTAT; DNA; ENTINOSTAT; GYRASE INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; PACLITAXEL; PANOBINOSTAT; RITUXIMAB; ROMIDEPSIN; ST2782; ST3595; TEMSIROLIMUS; TRASTUZUMAB; TRICHOSTATIN A; TUBACIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOMA CELL; DNA DAMAGE; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; GLIOMA CELL; HUMAN; LYMPHOMA CELL; MEDULLOBLASTOMA; NONHUMAN; OVARY CARCINOMA; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SENSITIZATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA DAMAGE; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICROTUBULES; NEOPLASMS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84858006066     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.11.010     Document Type: Review

References (97)

1. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Update 2007;10:59-67. (Pubitemid 46656478)
2. Sausville EA. The challenge of pathway and environment-mediated drug resistance. Cancer Metastasis Rev 2001;20:117-22. (Pubitemid 34074687)
3. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441-54.
4. Song S, Wientjes MG, Gan Y, Au JL-S. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-63. (Pubitemid 30639729)
5. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
7. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today 2009;14:942.
8. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehamn M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325:834-40.
9. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21.
10. Debatin K-M, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66. (Pubitemid 38638855)
11. Kim IA, No M, Lee JM, Shin JH, Oh JS, Choi EJ, et al. Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. Radiother Oncol 2009;92:125-32.
12. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009;280:125-33.
13. Chen C-S, Wang Y-C, Yang H-C, Huang P-H, Kulp SK, Yang C-C, et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007;67:5318-27. (Pubitemid 46997271)
14. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300. (Pubitemid 37413470)
15. Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 2006;12:940-9. (Pubitemid 43259877)
16. Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 2010;107:20003-8.
17. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100:4389-94. (Pubitemid 36457739)
18. Zuco V, Benedetti V, De Cesare M, Zunino F. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response. Int J Cancer 2010;126:1246-55.
19. Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, et al. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ 2004;11:280-9. (Pubitemid 38313137)
20. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006;5:1967-74. (Pubitemid 44336568)
21. Hacker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, et al. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 2011;30:2275-81.
22. Henderson C, Brancolini C. Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug resistance phenotype. Drug Resist Update 2003;6:247-56. (Pubitemid 37493781)
23. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52. (Pubitemid 47255934)
24. Lee J-H, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 2010;107:14639-44.
25. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009;274:169-75.
26. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, et al. Inhibition of histone deacetylses in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 2010;70:4470-80.
27. Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, et al. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem 2009;44:1900-12.
28. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006;5:2767-76. (Pubitemid 44849003)
29. Dietrich CS, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R, et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol 2010;116:126-30.
30. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 2008;99:376-84. (Pubitemid 351228495)
31. Modesitt SC, Parsons SJ. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? Gynecol Oncol 2010;119:351-7.
32. Asadollahi R, Hyde CAC, Zhong XY. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol 2010;118:81-7.
33. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon M, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8. (Pubitemid 34563539)
34. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-7.
35. Zuco V, Zunino F. Cyclic pifithrin-a sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia 2008;10:587-96. (Pubitemid 351770302)
36. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005;65:1918-24. (Pubitemid 40478621)
37. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
38. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010;16:1701-8.
39. Facchinetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CAM. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004;9:573-82. (Pubitemid 39158633)
40. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med 2005;11:77-83.
41. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylase induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med 2005;11:71-6. (Pubitemid 40215840)
42. Gillespie S, Borrow J, Zhang XD, Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 2006;11:2251-65. (Pubitemid 44885400)
43. Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007;313:2378-88. (Pubitemid 46891468)
44. Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009;45:2425-38.
45. Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, et al. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 2010;9:246-56.
46. Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with IFN-g to restore caspase 8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009;28:3097-110.
47. Inoue S, Harper N, Walewska R, Dyer MJS, Cohen GM. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 2009;8:3088-97.
48. Morales JC, Ruiz-Magana MJ, Carranza D, Ortiz-Ferron G, Ruiz-Ruiz C. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett 2010;297:91-100.
49. Voltz E, Gronemeyer H. A new era of cancer therapy: cancer cell targeted therapies are coming of age. Int J Biochem Cell Biol 2008;40:1-8. (Pubitemid 350052667)
50. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009;114:380-93.
51. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004;65:571-81. (Pubitemid 38264024)
52. Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis thorugh p44/42 MAP kinase inactivation and abrogation of p21 (CIP1/WAF1) induction rather than AKT inhibition. Oncogene 2003;22:6231-42. (Pubitemid 37281653)
53. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sakumar S, Brodie AMH. Functional activation of the estrogen receptor-a and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011;71:1893-903.
54. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 2000;60:6890-4. (Pubitemid 32059160)
55. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005;11:6382-9. (Pubitemid 41262970)
56. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003;2:971-84.
57. Marx C, Berger C, Xu F, Amend C, Scott GK, Hann B, et al. Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol 2006;4:273-84. (Pubitemid 44083582)
58. Labonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, et al. The Dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor Panobinostat in colorectal cancer models. Cancer Res 2011;71:3635-48.
59. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011;226:2378-90.
60. Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004;10:4991-7. (Pubitemid 39099772)
61. Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, et al. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk Res 2011;35:1212-8.
62. Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, et al. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood 2010;115:4217-25.
63. Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate Hsp90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 2009;69:6941-50.
64. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007;13:4882-90. (Pubitemid 47294796)
65. Nguyen A, Su L, Campbell B, Poulin NM, Nielsen TO. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009;2009:794901.
66. Giommarelli C, Zuco V, Favini E, Pisano C, Dal Piaz F, De Tommasi N, et al. The enhancement of antiproliferative and pro-apoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci 2010;67:995-1004.
67. Mahalingam D, Medina EC, Esquivel 2nd JA, Espitia CM, Smith S, Oberheu K, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010;16:141-53.
68. Verheul HMW, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, et al. Combination strategy targeting the hypoxia inducible factor-1a with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 2008;14:3589-97.
69. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010;16:4094-104.
70. Perego P, Cossa G, Zuco V, Zunino F. Modulation of cell sensitivity to antitumor agents by targeting survival pathways. Biochem Pharmacol 2010;80:1459-65.
71. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38. (Pubitemid 38030301)
72. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, et al. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008;14:7340-7.
73. Lin Z, Bazzarro M, Wang MC, Chan KC, Peng S, Roden RB. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009;15:570-7.
74. Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, et al. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 2009;284:11171-83.
75. Li D, Marchenko ND, Moll UM. SAHA shows preferentially cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011;1-10.
76. Milli A, Cecconi D, Campostrini N, Timperio AM, Zolla L, Righetti SC, et al. A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells. Biochim Biophys Acta 2008;1784:1702-10.
77. Leimore M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010;10:462-70.
78. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH, Romidepsin. (Istodax, NSC630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot 2011;64:525-31.
79. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 2010;24:1760-8.
80. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
81. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
82. Gaumes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 2006;4:563-73. (Pubitemid 44341366)
83. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007;139:385-97. (Pubitemid 47512171)
84. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011;2011:875824.
85. Bali P, Prampt M, Bradner J, Balasis M, Fiskus W, GuoF. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34. (Pubitemid 41040705)
86. Shan B, Yao T, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, et al. Requirement of HDAC6 for transforming growth factor-β1-induced epithelial-mesenchymal transition. J Biol Chem 2008;283:21065-73.
87. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741-51.
88. Sabbah M, Emami S, Redehilh G, Julien S, Prevost G, Zimber A, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Update 2008;11:123-51.
89. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Cell 2008;18:291-7.
90. Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, et al. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. Clin Cancer Res 2010;16:3844-53.
91. Qian X, Ara G, Mills E, La Rochelle WJ, Lichenstein HS, Jeffers M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 2008;122:1400-10. (Pubitemid 351287242)
92. Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol 2009;23:1963-72.
93. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011;7:263-83.
94. Fujisawa T, Joshi BH, Puri RK. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. J Transl Med 2011;9:37.
95. Lai MD, Chen CS, Yang CR, Yuan SY, Tsai JJ, Tu CF, et al. An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. Cancer Gene Ther 2010;17:203-11.
96. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature Rev Drug Discov 2006;5:769-84. (Pubitemid 44348499)
97. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010;9:3254-66.